Helus Pharma Director Eric So Receives 248,000 RSUs

What Happened

• Eric H. L. So, a director of Helus Pharma, received an award of 248,000 restricted stock units (RSUs) on September 30, 2026. The RSUs vested immediately upon grant. No per-share purchase price is reported for this award (typical for RSU grants); each RSU represents the right to receive one share of the company's common stock when settled.

Key Details

• Transaction date: 2026-09-30 (Grant/Award, code A)
• Report filed: 2026-10-01 (timely; within the usual Form 4 deadline)
• Shares/units granted: 248,000 RSUs
• Price: N/A for the grant (RSUs are award/compensation, not an open-market trade)
• Shares owned after transaction: Not specified in the data provided
• Footnotes:
  • F1: Confirms the grant of 248,000 RSUs on 9/30/2026 with immediate vesting.
  • F2: Each RSU converts to one share of common stock upon settlement.

Context

• RSU grants are a form of compensation; immediate vesting means the insider has the right to the underlying shares (subject to settlement and any company transfer restrictions). This is an award, not a buy or sell — it does not by itself indicate bullish or bearish trading intent.